Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports


Current news and events

Pål Kristian Selbo receives NOK 3.75 from Radforsk Investment Foundation

Pål Kristian Selbo
Pål Kristian Selbo

Radforsk Investment Foundation has granted five research projects a total amount of MNOK 4.95 to further develop exciting research projects within photodynamic treatment and photochemical internalization.
This year, one of the projects has been awarded a total of NOK 3.75 million over three years. It is a project led by researcher Pål Selbo at the Department of Cancer Research entitled «Novel Photobiological Strategies Counteracting Tumor Immune Escape».
Selbo has been interviewed (in Norwegian) for the Radium podcast on basis of the Radforsk support.

PANCAIM: A European consortium to improve pancreatic cancer treatment with artificial intelligence optimizing, integrating genomics and medical imaging

PANCAIM will optimize and integrate genomics and imaging phenomics using artificial intelligence (AI). The aim is to help clinical decision-makers to give the right treatment to the right patients at the right time. The PANCAIM project was granted >8 M€ where >1 M€ was granted OUS.

The PANCAIMs OUS team: Tero Aittokallio, Elin Kure, Gry A. Geitvik, Caroline Verbeke and Knut Jørgen Labori.

Fridtjof Nansen award 2021 for excellent research to Harald A. Stenmark

Harald A. Stenmark
Harald A. Stenmark

The Fridtjof Nansen award for excellence in science is for 2021 awarded to Professor Harald Alfred Stenmark for his outstanding research in the field of cellular and molecular biology, with particular focus on cancer research.

This prestigious prize is awarded to a Norwegian scientist, or a scientist residing in Norway, for scientific contributions of a high-level international importance. The award is given to inspire further work.

The award ceremony takes place at the annual meeting of The Norwegian Academy of Science and Letters in May.

Awarded 9 million NOK to study autophagy in prostate cancer

Nikolai Engedal
Nikolai Engedal

Nikolai Engedal was recently awarded 9 million NOK in Open project support from The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) 2020 call. The project aims to unravel the role of autophagy in prostate cancer formation and progression, to discover prognostic autophagy-related gene signatures and markers, and to identify autophagy-modulating drugs that can reduce cancer cell aggressiveness. Engedal is now starting up a project group in Eivind Hovig’s group at the Department of Tumor Biology.

Project from Weyergangs project group admitted to SPARK Norway

Anette Weyergang
Anette Weyergang

In the project entitled "A Novel Biomarker for Antibody Drug Conjugates" Weyergang and her team seeks to develop a diagnostic tool for better stratification of patients to novel targeted therapeutics including antibody drug conjugates.

SPARK is a Life Science`s innovation program build to increase the success rate of projects with high potential impact, addressing critical unmet needs. Project teams admitted to SPARK will be educated and advised on relevant processes for commercialization of their idea. They will also receive financial support (up to 500 000 NOK per year- maximum two years based on the accomplishment of milesones). 

Units and subpages

View all subunitsHide all subunits